11 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 14.4% per year over the past 5 years.
Net income has grown faster than revenue (100.9% vs 14.4% per year).
Operating margin has been roughly flat, at 19.8% in the latest year.
Financial health
Operating income covered interest expense 4.8× in the latest year, up from 3.1× 5 years ago.
Shareholder returns
Dividends have been paid for 10 consecutive years, consuming 230.9% of earnings.
The dividend has grown 43.4% per year over the past 5 years.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$2.1B
$71M
14.4%
19.8%
2.1%
1.3%
—
—
$115M
2024
$1.9B
-$36M
12.2%
19.3%
-1.6%
-0.8%
—
—
$77M
2023
$1.7B
-$77M
10.0%
18.4%
-6.1%
-1.7%
—
—
$43M
2022
$1.4B
-$73M
9.3%
21.4%
-5.2%
-1.5%
—
—
$65M
2021
$1.1B
-$53M
8.3%
19.0%
-3.4%
-1.2%
—
—
$82M
2020
$1.1B
$2M
7.0%
20.4%
0.2%
0.1%
—
—
$113M
2019
$1.1B
-$5M
11.9%
20.1%
-0.8%
-0.5%
—
—
$53M
2018
$37M
-$8M
18.5%
0.0%
—
-0.9%
—
—
$35M
2017
$6M
$541000
24.4%
0.0%
—
0.1%
—
—
$7M
2016
$0
-$5M
—
—
-5.9%
-3.8%
—
—
$2M
2015
—
$0
—
—
0.0%
0.0%
—
—
$202000
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Jun '26
$635M
$31M
17.3%
21.6%
0.8%
0.5%
—
—
$157M
Mar '26
$610M
$24M
16.0%
20.6%
0.7%
0.4%
—
—
$119M
Dec '25
$564M
$11M
14.8%
19.8%
0.3%
0.2%
—
—
$115M
Sep '25
$532M
$56M
14.6%
19.9%
2.1%
1.2%
—
—
$147M
Jun '25
$501M
$10M
15.0%
20.6%
0.4%
0.2%
—
—
$133M
Mar '25
$497M
-$7M
13.0%
19.0%
-0.3%
-0.2%
—
—
$86M
Dec '24
$497M
-$32M
13.3%
20.0%
-1.4%
-0.7%
—
—
$77M
Sep '24
$477M
-$4M
12.5%
19.6%
-0.2%
-0.1%
—
—
$68M
Jun '24
$458M
$2M
12.1%
19.4%
0.1%
0.0%
—
—
$52M
Mar '24
$452M
-$4M
10.7%
18.2%
-0.2%
-0.1%
—
—
$77M
Dec '23
$433M
-$27M
11.1%
19.5%
-2.2%
-0.6%
—
—
$43M
Sep '23
$416M
-$6M
10.0%
18.0%
-0.5%
-0.1%
—
—
$35M
Jun '23
$411M
-$12M
9.3%
19.6%
-0.9%
-0.3%
—
—
$48M
Mar '23
$409M
-$26M
9.4%
16.4%
-1.9%
-0.5%
—
—
$41M
Dec '22
$399M
-$48M
9.5%
19.3%
-3.4%
-1.0%
—
—
$65M
Sep '22
$368M
-$14M
8.4%
20.0%
-0.9%
-0.3%
—
—
$79M
Jun '22
$326M
-$17M
9.2%
23.8%
-1.1%
-0.4%
—
—
$59M
Mar '22
$319M
-$3M
10.0%
23.1%
-0.2%
-0.1%
—
—
$75M
Dec '21
$308M
-$23M
9.7%
23.8%
-1.5%
-0.5%
—
—
$82M
Sep '21
$287M
-$5M
10.5%
18.3%
-1.0%
-0.5%
—
—
$110M
Valuation over time
How the market has priced AHR against its own fundamentals since 2024-02 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has risen from 144.8× (Dec '25) to 171.6× (Sep '26).
The price-to-sales ratio has risen from 1.8× (Feb '24) to 5.8× (Sep '26).
The dividend yield has fallen from 2.6% (Feb '24) to 1.3% (Sep '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Dividend yield (%)
Dividend yield %
Frequently asked questions
Is AHR growing its revenue and profit?
Over the past 5 years, American Healthcare Reit, Inc.'s revenue has grown 14.4% per year, and net income grown 100.9% per year. These are computed facts, not advice.
How much debt does AHR have?
As of FY2025, American Healthcare Reit, Inc. reported — of total debt against $115M of cash; operating income covered interest expense 4.8×.
What is AHR's profit margin?
In FY2025, gross margin was 14.4%, operating margin 19.8%, and net margin 3.4%.
What is AHR's P/E ratio?
As of Sep '26, American Healthcare Reit, Inc. traded at a price-to-earnings ratio of about 171.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.